At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 201 enrolled
Drug / intervention
Neostigmine+glycopyrrolate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Controlled Assessor Blinded Clinical Trial of Sugammadex Versus Neostigmine /Glycopyrrolate for Reversal of Rocuronium Induced Neuromuscular Blockade: Time to Discharge From Post Anesthesia Care Unit and Patient Satisfaction With Recovery
In Brief
A Phase 3 clinical trial evaluating Neostigmine+glycopyrrolate and Sugammadex for Surgery. Completed, enrolled 201 participants across 4 sites.
Detailed Summary
The purpose of this study is to compare two different medications (neostigmine/glycopyrrolate and sugammadex) to see if one drug improves patient comfort regarding the return of muscle strength after surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSurgery
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
Enrollment StartApr 2017
First PostedApr 2017
Primary CompletionMar 2022
TodayJul 2026
First PostedApr 17, 2017
Enrollment StartApr 7, 2017
Primary CompletionMar 3, 2022
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 9.2 years ago
Interventions
Neostigmine+glycopyrrolatedrug
At the conclusion of surgery neuromuscular blockade reversed with neostigmine/glycopyrrolate
Sugammadexdrug
At the conclusion of surgery neuromuscular blockade reversed with sugammadex